BioLife Solutions, Inc. (NASDAQ: BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapies (“CGT”) and broader biopharma markets, today announced that it has executed a co-marketing agreement with Coriell Institute of Medical Research.
Under the terms of the agreement, BioLife Solutions, under its SciSafe® brand, will promote Coriell’s biospecimen processing services and Coriell will promote BioLife’s biologic storage services to the scientific research and biopharma markets. The parties will share revenue generated from these co-marketing activities.
Garrie Richardson, SciSafe founder and member of BioLife’s executive team, commented, “This agreement and related cross-marketing activities will enable Coriell and BioLife to better serve our respective customers by providing a more complete and complementary offering in the form of biostorage and lab services such as biospecimen collection kitting, cell line establishment, DNA extraction, and custom laboratory services.”
Kathryn H. Driesbaugh, PhD, Director of Repository Operations at Coriell, remarked, “Coriell is excited about our relationship with SciSafe that will provide more value to the biopharma research community. We look forward to enhancing our offerings via this agreement by leveraging our strong laboratory infrastructure to better support the research community towards the development of life-improving and lifesaving therapies.”
Founded in 1953, the Coriell Institute for Medical Research is a nonprofit research institute dedicated to improving human health through biomedical research. Coriell scientists lead research in personalized medicine, cancer biology, epigenetics, and the genomics of opioid use disorder.
Coriell also hosts one of the world’s leading biobanks—comprising collections for the National Institutes of Health, disease foundations and private clients—and distributes biological samples and offers research and biobanking services to scientists around the globe. To facilitate drug discovery and disease study, the Institute also develops and distributes collections of induced pluripotent stem cells.